Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 9/26/2013 8:42:15 PM : Underperform Start Price: $6.70 DYAX Score: +9.95

Technically very over bought.

Recs

1
Member Avatar gringo33339 (< 20) Submitted: 4/26/2013 5:32:29 PM : Outperform Start Price: $2.73 DYAX Score: +129.05

Buying opportunity today for this stock which will benefit greatly if LLY sees success in its Ramu pipeline drug candidate.

Recs

1
Member Avatar DEWBMW (< 20) Submitted: 5/24/2012 12:59:28 AM : Outperform Start Price: $1.69 DYAX Score: +257.69

Should break even on cash flow in 2013. Great time to get in. Only company I know that makes a drug for HAE.

Recs

0
Member Avatar stainsolution (71.46) Submitted: 4/9/2012 7:42:31 PM : Outperform Start Price: $1.57 DYAX Score: +293.55

Bio play

Recs

0
Member Avatar RBuskey106 (63.41) Submitted: 3/21/2012 11:29:57 AM : Outperform Start Price: $1.58 DYAX Score: +292.86

Chart looking good

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 3/11/2011 12:51:19 PM : Outperform Start Price: $1.57 DYAX Score: +286.01

Should get some play.

Recs

0
Member Avatar wofaintagain (25.02) Submitted: 10/15/2009 12:34:34 PM : Underperform Start Price: $3.22 DYAX Score: -38.20

until drug approval

Recs

0
Member Avatar biomedeng (36.72) Submitted: 12/31/2007 8:06:33 PM : Outperform Start Price: $3.87 DYAX Score: +42.13

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

Recs

0
Member Avatar doggetla (69.68) Submitted: 10/26/2007 6:57:24 PM : Outperform Start Price: $4.50 DYAX Score: +22.69

great bio-tech partners - with lots of "magic beans" in pipeline

Recs

0
Member Avatar Dwaterman86 (33.70) Submitted: 10/4/2007 3:39:25 PM : Underperform Start Price: $3.82 DYAX Score: -49.46

better off investing in magic beans

Recs

0
Member Avatar hendrikvanlaar (< 20) Submitted: 9/11/2007 4:25:01 AM : Outperform Start Price: $3.98 DYAX Score: +34.93

finding a partner to sell their top drug will boost the stock (the successful completion of phase III sent the stock up by 50% in a day, but that didn't last. Make use of it)

Recs

0
Member Avatar fatcanibal (35.87) Submitted: 6/14/2007 4:17:27 PM : Outperform Start Price: $4.55 DYAX Score: +19.79

Well organized and focused

Recs

0
Member Avatar misterp946 (32.19) Submitted: 5/22/2007 3:41:43 PM : Outperform Start Price: $4.34 DYAX Score: +26.13

Hot New Products....stock took a beating....when Genzyme deal feel through...This stock due for a nice come back....sell on announcement

Recs

0
Member Avatar jgonzz (< 20) Submitted: 5/18/2007 3:11:38 PM : Outperform Start Price: $4.45 DYAX Score: +21.76

Too many promising projects inside their pipeline.

Recs

0
Member Avatar carmangar (< 20) Submitted: 4/26/2007 9:38:55 PM : Outperform Start Price: $4.48 DYAX Score: +18.05

Development of new medicine, pending outcome of further research and medical experimentation.

Recs

1
Member Avatar majakblue (< 20) Submitted: 4/14/2007 3:19:13 PM : Underperform Start Price: $6.19 DYAX Score: +26.40

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Recs

0
Member Avatar j3bajric (< 20) Submitted: 4/13/2007 2:16:00 PM : Outperform Start Price: $5.92 DYAX Score: -22.19

If it gets approved money will flow.

Recs

0
Member Avatar wbahl (85.31) Submitted: 4/13/2007 11:05:35 AM : Outperform Start Price: $6.21 DYAX Score: -27.60

This company researches cancer and is very successful.

Recs

1
Member Avatar beefsteakfarmer (29.60) Submitted: 3/13/2007 10:42:54 AM : Outperform Start Price: $3.95 DYAX Score: +29.57

The immediate future may not be encouraging but the long term will outperform the s&p. Look for the place to get in and then exit when the dx-88 sends the stock soaring for a little while.

Recs

0
Member Avatar mesomatt (< 20) Submitted: 2/17/2007 10:06:04 AM : Outperform Start Price: $4.65 DYAX Score: +8.82

this new drug that they are coming out with will most likely get accepted to distribute throughout the public. if it does, the prices will soar for the next few months. im not sure how the long term will do though.

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement